Bio-ink for 3D printing

By using maleimide-containing polymers with bithiol-containing crosslinking agents, the problem of restricted interaction between cells and ECM mimetics and UV crosslinking is harmful to cells in 3D bioprinting is solved, and the problem of rapid and Non-toxic form hydrogels, supporting high cell viability and efficient printing.

CN112752788BActive Publication Date: 2024-11-26NEWSOUTH INNOVATIONS PTY LTD
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN201980060575.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2018-07-24
Filing Date
2019-07-23
Publication Date
2024-11-26
Estimated Expiration
2039-07-23

AI Technical Summary

Technical Problem

In the existing 3D bioprinting technology, the interaction between cells and ECM mimics is limited, and the crosslinking reaction caused by UV is harmful to cells, resulting in damage to cell viability and problems of high complexity and low yield.

Method used

A 3D printed hydrogel formed by a maleimide-containing polymer crosslinked with a bithiol-containing crosslinking agent was developed, which is formed through a rapid non-toxic chemical pathway, possessing biocompatible properties, and Supports high cell viability under physiological conditions.

Benefits of technology

It realizes the rapid and non-toxic formation of uniform hydrogels in 3D printing, supports the uniform distribution of high-density and high-vibration cells, avoids the use of UV radiation and free radicals, and improves cell biocompatibility and printing efficiency.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0002978135910000081
    Figure BDA0002978135910000081
  • Figure BDA0002978135910000091
    Figure BDA0002978135910000091
  • Figure BDA0002978135910000101
    Figure BDA0002978135910000101
Patent Text Reader

Abstract

The present technology relates to a 3D printing hydrogel formed by cross-linking a maleimide-containing polymer using a dithiol-containing cross-linking agent having at least two thiol functional groups, a method for preparing the 3D printing hydrogel, and uses thereof.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Related Applications

[0002] This application claims the benefit of Australian Provisional Patent Application No. 2018902674, filed on July 24, 2018, entitled “Bio-ink for 3D printing”, the entire contents of which are incorporated herein by reference in their entirety. Technical Field

[0003] The present technology generally relates to bio-inks for 3D printing. In particular, the present technology relates to 3D printing hydrogels formed from polymers cross-linked using a cross-linking agent, methods for preparing the hydrogels, and uses thereof. Background Art

[0004] Cells exist three-dimensionally in the body within an extracellular matrix (ECM). The interactions between cells and the ECM play an important role in controlling the biological characteristics and behavior of cells. In cancer biology, three-dimensional (3D) in vitro cell culture assays are used to culture cells in an environment that closely mimics the natural environment of the cells. Such assays maintain physiological cell-cell and cell-matrix interactions that are not present in two-dimensional monolayer cultures.

[0005] 3D bioprinting uses 3D technology to combine cells with other biomaterials to prepare synthetic structures that can mimic the ECM. Generally, 3D bioprinters use drop-on-demand or extrusion printing techniques to print 3D in vitro assays. Although drop-on-demand bioprinting has been reported to maintain high cell viability during printing, it is still less commonly used compared to its extrusion technology due to the low viscosity and cell density of current 3D bioinks.

[0006] Hydrogels, both synthetic and natural, have been widely used as ECM mimics. In particular, synthetic hydrogels are highly reproducible and offer good control over physical and cellular response properties, making them ideal ECM mimics for in vitro studies. Current methods for manually creating 3D in vitro assays mainly use or collagen as ECM mimics. Other widely used materials are hyaluronic acid, chitosan, and alginic acid. Because they are derived from natural products, natural hydrogels are generally biocompatible and carry the necessary biomolecules for cell-matrix interactions in some cases. However, natural hydrogels are limited as ECM mimics because they are susceptible to batch-to-batch variability, lack physical and biochemical modularity, and / or are difficult to handle.

[0007] In order to overcome the various limitations of natural hydrogels, various synthetic hydrogels have been prepared. In particular, covalently cross-linked synthetic hydrogels can provide stronger and more physically precise systems than natural hydrogels. However, many of these synthetic hydrogels lack biochemical properties that promote cell-matrix interactions. Further, in order to apply covalently cross-linked synthetic hydrogels to 3D bioprinting of cells, the material should be biocompatible so that cells can be printed in situ within the hydrogel. For example, although poly(acrylamide) is a biocompatible synthetic hydrogel used in cell biology (Caliari and Burdick, 2016), the corresponding hydrogel precursor is not biocompatible and is therefore not suitable for 3D bioprinting of cells.

[0008] Current 3D bioprinting methods include UV-induced free radical cross-linking reactions that can rapidly form hydrogels (Murphy and Atala, 2014; Donderwinkel et al., 2017: Jungst et al., 2016Lowe et al., 2014). For example, inkjet printing of photolinkable acrylated PEG and peptides has been found to be suitable for generating 3D hydrogel structures for encapsulating mesenchymal stem cells (Gao et al., 2017; Gao et al., 2015). However, although this approach has been demonstrated for potential use in 3D bioprinting of living cells, the use of UV irradiation to induce photocrosslinking can cause damage to DNA in living organisms, and the free radicals generated can also damage sensitive cells.

[0009] In recent years, 3D bioprinting technology has made significant progress, which has the potential to alleviate the limitations of current 3D in vitro cell culture analysis. However, although the benefits of 3D printed cell culture have been well established, the application of 3D printed in vitro analysis in cell biology is still limited by its complexity, labor-intensiveness and low yield. Therefore, there is a need for alternative ECM mimics for 3D bioprinting.

[0010] Overview

[0011] The present inventors have developed bio-inks suitable for 3D printing that are biocompatible and can rapidly form hydrogels via a substantially non-toxic chemical pathway.

[0012] In a first aspect, the present technology provides a 3D printed hydrogel formed from a maleimide-containing polymer cross-linked using a dithiol-containing cross-linker having at least two thiol functional groups.

[0013] The dithiol-containing cross-linking agent may include two or more thiol functional groups.

[0014] In one embodiment, a hydrogel is formed by combining a solution comprising a maleimide-containing polymer (polymer bioink) and a solution comprising a dithiol-containing cross-linker (activator) using a 3D printer.

[0015] In one embodiment, the 3D printed hydrogel is formed in about 30 minutes or less, 10 minutes or less, 1 minute or less, 30 seconds or less, 10 seconds or less, 1 second or less from the time of printing the polymer bio-ink and the activator.

[0016] In one embodiment, the polymer bio-ink is biocompatible with cells.

[0017] In one embodiment, the activating agent is biocompatible with the cell.

[0018] In one embodiment, the polymer bio-ink and the activating agent form a hydrogel that is biocompatible with cells when combined during 3D printing.

[0019] In one embodiment, the maleimide-containing polymer is selected from maleimide-containing polysaccharides, such as polymers containing fructose, sucrose or glucose monomers; synthetic polymers, such as poly(ethylene glycol) (PEG) maleimide, poly(hydroxyethyl methacrylate (PHEMA) maleimide, poly(ε-caprolactone) (PCL) maleimide, poly(vinyl alcohol) (PVA) maleimide, poly(vinyl pyrrolidone) (PVP) maleimide, poly(N-isopropylacrylamide) (NIPAAM) maleimide, poly(propylene fumarate) (PPF) maleimide, poly(ethyleneimine) (PEI) maleimide, poly(3-methacrylamidopropyl) trimethylammonium (PMAETMA) maleimide, maleimide, poly(L-lysine) (PLL) maleimide, poly(acrylic acid) (PAA) maleimide, poly(styrene sulfonate) (PSS) maleimide, poly(acrylic acid-stat-dimethylaminoethyl methacrylamide) (P(AA-stat-DMAEMA)) maleimide, and poly(methacrylic acid arginine) maleimide, or derivatives thereof; maleimide-containing biopolymers, such as gelatin maleimide, cellulose maleimide, hyaluronic acid maleimide and alginate maleimide; maleimide-containing nucleobase polymers (i.e., polymers of adenine, thymine, guanine and / or cytosine repeating units containing maleimide); or any combination thereof.

[0020] In one embodiment, the maleimide-containing polymer comprises poly(vinyl alcohol) (PEG) maleimide.

[0021] In one embodiment, the maleimide-containing polymer comprises gelatin maleimide.

[0022] In one embodiment, the dithiol-containing cross-linking agent is selected from a synthetic polymer, a biopolymer, a small molecule, a biologically active molecule, or any combination thereof.

[0023] In one embodiment, the synthetic polymer is selected from PEG dithiol, poly (N-isopropylacrylamide) -dithiol (NIPAAM-dithiol), poly (acrylic acid) -dithiol, poly (methacrylic acid) -dithiol, poly (styrene sulfonate) -dithiol, poly (amide) -dithiol, or any combination thereof. In one embodiment, the dithiol-containing cross-linking agent is PEG-dithiol.

[0024] In one embodiment, the biopolymer is selected from thiol-gelatin, thiol-cellulose, thiol-chitosan, thiol-hyaluronic acid, or any combination thereof.

[0025] In one embodiment, the small molecule is dithiothreitol (DTT).

[0026] In one embodiment, the bioactive molecule is selected from a short-chain peptide having at least two cysteine ​​groups, an inert short-chain peptide, an enzyme-responsive short-chain peptide, a matrix metalloproteinase (MMP)-responsive peptide, or any combination thereof.

[0027] In one embodiment, the dithiol-containing bioactive molecule is selected from MMP-responsive dicysteine ​​peptides.

[0028] In one embodiment, the MMP-responsive peptide may be GCIPVSLRSGCG, GCRDGPQGIWGQDRCG, GCRDPLGLDRCG, GCRDEAPLKQDRCG, or any combination thereof.

[0029] In one embodiment, the maleimide-containing polymer is PEG-maleimide; and the dithiol-containing cross-linker is selected from PEG-dithiol, or a MMP-responsive peptide, or a combination thereof.

[0030] In one embodiment, the maleimide-containing polymer is PEG-maleimide substituted with at least one bioactive molecule selected from RGD, YIGSR and IKVAV, and the dithiol-containing crosslinker is selected from PEG-dithiol, MMP-responsive peptide, or a combination thereof.

[0031] In one embodiment, the MMP-responsive peptide is GCIPVSLRSGCG, GCRDPLGLDRCG, or a combination thereof.

[0032] In one embodiment, the maleimide-containing polymer is gelatin maleimide and the dithiol-containing cross-linker is PEG-dithiol.

[0033] In one embodiment, the maleimide-containing polymer is gelatin maleimide and the dithiol-containing cross-linker is PEG-dithiol.

[0034] In one embodiment, the molar ratio of the maleimide-containing polymer to the dithiol-containing crosslinker ranges from about 10:1 to about 1: 10. The ratio of thiol groups in the dithiol-containing crosslinker to maleimide groups in the maleimide-containing polymer may be greater than about 60%.

[0035] The hydrogel is formed by printing a drop of bio-ink onto a substrate and then printing a drop of activator to form a hydrogel droplet, or applying a drop of activator to a substrate and then printing a drop of polymer bio-ink to form a hydrogel. The printing steps are repeated to form a hydrogel. During the printing process, the cells can be contained in the polymer bio-ink, the activator, or both the polymer bio-ink and the activator. In addition or alternatively, the cells can be contained in a cell culture medium. The cell culture medium can be included in the polymer bio-ink, the activator, or it can be separated from the polymer bio-ink and the activator. For example, the cell culture medium can be suspended between the 3D printed hydrogel layers formed by the polymer bio-ink and the activator, or it can be deposited on the surface of the hydrogel.

[0036] In one embodiment, the substrate is selected from any suitable container. Examples include microtiter plates of different well structures (6, 24, 48 and 96 wells), microtiter plates with cover glass bottoms of different well structures (6, 24, 48 and 96 wells), fluorodishes of various sizes, chamber slides of different well structures (1, 2, 4, 8 and 16), cover slides or microscope slides. The container may be suitable for containing, maintaining or growing cells.

[0037] In one embodiment, the 3D printed hydrogel further comprises a bioactive molecule. The bioactive molecule may be connected to a maleimide-containing polymer or a dithiol-containing crosslinker, or may be combined with a maleimide-containing polymer and a dithiol-containing crosslinker. In addition or alternatively, free bioactive molecules may be present in the 3D printed hydrogel. Free bioactive molecules may be present in polymer bio-inks, activators; or may be present in polymer bio-inks and activators. The bioactive molecule may be selected from peptides, MMP-responsive peptides, proteins, polysaccharides, drugs, therapeutic agents, antibodies, small molecule inhibitors, kinase inhibitors, phosphatase inhibitors, antigens, pathogens, platelets, growth factors, cytokines, amino acids, nutrients, conditioned medium, antibiotics, antiviral drugs, RNA, and any combination thereof. Nanoparticles may also be added to the 3D printed hydrogel.

[0038] In one embodiment, the biologically active molecule is selected from CRGDS, CIKVAV, CYIGSR, VEGF containing a C-terminal unpaired cysteine, a protein (e.g., laminin, collagen), and a MMP-responsive peptide (e.g., GCIPVSLRSGCG, GCRDGPQGIWGQDRCG, GCRDPLGLDRCG, GCRDEAPLKQDRCG); and any combination thereof.

[0039] In one embodiment, the 3D printed hydrogel further comprises a cell culture medium. Examples of suitable culture media include Dulbecco's modified Eagle's medium (DMEM), minimum essential medium (MEM), Iscove's modified Dulbecco's medium (IMDM), Media 199, Ham F10, Ham F12, McCoy 5A, and Roswell Park Memorial Institute (RPMI) culture medium. The cell culture medium may be present in the polymer bio-ink, the activator, or both in the polymer bio-ink and in the activator.

[0040] In one embodiment, the hydrogel contains cells.

[0041] In one embodiment, the cells are present in a polymer bio-ink, in an activating agent, in both a polymer bio-ink and an activating agent, or in a separate culture medium prior to 3D printing to allow for printing of a cell-containing hydrogel.

[0042] In one embodiment, the cells are suspended within a portion of the hydrogel.

[0043] In one embodiment, the cells are suspended substantially uniformly throughout the hydrogel.

[0044] The concentration of printed cells can range from about 1×10 5 ~About 5×10 8 It will be appreciated that lower or higher concentrations of cells can be printed to form printed hydrogels containing cells.

[0045] In one embodiment, the cell can be selected from hepatocytes, gastrointestinal cells, pancreatic cells, kidney cells, lung cells, tracheal cells, vascular cells, skeletal muscle cells, cardiomyocytes, skin cells, smooth muscle cells, connective tissue cells, corneal cells, urogenital cells, breast cells, germ cells, endothelial cells, epithelial cells, fibroblasts, neural cells, Schwann cells, adipocytes, osteocytes, bone marrow cells, chondrocytes, pericytes, mesothelial cells, endocrine tissue-derived cells, stromal cells, stem cells, progenitor cells, lymphocytes, blood cells, endoderm-derived cells, ectoderm-derived cells or mesoderm-derived cells, or any combination thereof. The cell can include a cancer cell.

[0046] In a second aspect, the present technology provides a method for preparing a 3D printed hydrogel, the method comprising the following steps:

[0047] Providing a polymer bio-ink, the polymer bio-ink comprising a maleimide-containing polymer;

[0048] providing an activator, the activator comprising a dithiol-containing cross-linking agent, the cross-linking agent having at least two thiol functional groups; and

[0049] Printing polymer bio-ink and activator to form 3D printed hydrogel.

[0050] In one embodiment, the method further comprises providing cells to form a 3D printed hydrogel containing cells. The cells can be present in the polymer bio-ink, in the activating agent, in both the polymer bio-ink and the activating agent, or in a separate culture medium prior to 3D printing.

[0051] In one embodiment, the 3D printed hydrogel is formed in 30 minutes or less, or 10 minutes or less, or 1 minute or less, or 30 seconds or less, or 10 seconds or less, or 1 second or less from the start of printing of the polymer bio-ink and the activator.

[0052] In one embodiment, the polymer ink, the activator, or both are adjusted to about pH 7.4 prior to printing.

[0053] In one embodiment, NaOH is used to adjust the pH.

[0054] This method can be used to prepare a 3D printed hydrogel according to the first aspect.

[0055] In a third aspect, the present technology provides a 3D printing kit, the kit comprising:

[0056] A polymer bio-ink comprising a maleimide-containing polymer; and

[0057] The activator comprises a dithiol-containing cross-linking agent, wherein the cross-linking agent has at least two thiol functional groups.

[0058] In one embodiment, the kit further comprises a cell.

[0059] In one embodiment, the kit further comprises a printed substrate.

[0060] In a fourth aspect, the present technology provides a cell analysis method, comprising a 3D printed hydrogel containing cells according to the first aspect.

[0061] In a fifth aspect, the present technology provides a use of a cell-containing 3D printed hydrogel for cell analysis according to the first aspect.

[0062] definition

[0063] The following are some definitions of terms used in the prior art that may help understand the present invention. These definitions are intended to be general definitions and should not in any way limit the scope of the present invention to only those terms, but are provided for a better understanding of the following description.

[0064] Unless the context requires otherwise or specifically stated otherwise, integers, steps or elements of the invention recited herein as the singular integer, step or element expressly encompass both the singular and the plural of the recited integer, step or element.

[0065] As used herein, the term "about" means ± 10% of the stated value.

[0066] As used herein, the terms "cross-linker" and "cross-linking agent" are used interchangeably and refer to chemical compounds that are capable of covalently cross-linking maleimide-containing polymers. The cross-linking agent of the present technology contains at least two thiol functional groups, referred to herein as a "bis-thiol-containing cross-linking agent" or "bis-thiol-containing cross-linking agent". The bis-thiol-containing cross-linking agent may contain more than two thiol functional groups, such as three, four, five, six or more thiol functional groups.

[0067] As used herein, the term "polymer bio-ink" refers to a solution, preferably an aqueous solution, comprising a maleimide-containing polymer, or a combination of two or more maleimide-containing polymers. As used herein, the term "activator" refers to a solution, preferably an aqueous solution, comprising at least one dithiol-containing cross-linking agent. When the polymer bio-ink and the activator of the present technology are mixed, i.e., during 3D printing, a thiol-maleimide cross-linking reaction occurs to form a hydrogel.

[0068] As used herein, the term "biocompatible" with respect to a substance means that the substance is substantially non-toxic to living cells or tissues.

[0069] As used herein, the term "biologically active molecule" refers to a molecule having biological activity that can be used with cultured cells.

[0070] As used herein, the term "cell polymer bio-ink" refers to cells mixed with a polymer bio-ink comprising at least one maleimide-containing polymer. As used herein, the term "cell activator" refers to cells mixed with an activator comprising at least one dithiol-containing cross-linker. The cell polymer bio-ink and cell activator of the present technology can be an aqueous solution of bioactive molecules in which one or more types of cells are suspended and can remain suspended throughout the 3D bioprinting process.

[0071] The term "cell culture medium" refers to a liquid that can be used to store, maintain, grow or culture cells.

[0072] As used herein, the term "drop-on-demand" in relation to 3D bioprinting refers to a printing process in which the delivery of bio-ink is based on the generation of discrete droplets. Drop-on-demand bioprinting may include, but is not limited to, thermal inkjet, piezoelectric inkjet, and microvalve-based bioprinting.

[0073] If ranges of values ​​are given throughout the description and claims of the present application, said ranges are intended to include any value within that range.

[0074] Any discussion of documents, acts, materials, devices, articles or the like in this specification is intended solely to provide a background to the present invention. It is not to be taken as an admission that any or all of these matters form part of the prior art base or were common general knowledge in the field relevant to the present invention as it existed before the priority date of each claim of this specification.

[0075] In this application, unless the context requires otherwise, the word "comprise" or variations such as "include" or "comprising" will be understood to imply the inclusion of a stated element, integer or step, or a group of elements, integers or steps, but not the exclusion of any other element, integer or step, or a group of elements, integers or steps.

[0076] The term "consisting of" means "consisting only of", i.e., including and limited to the stated elements, integers or steps, excluding any other elements, integers or steps. The term "consisting essentially of" means including the stated elements, integers or steps, but may also include other elements, integers or steps that do not substantially change or contribute to the working of the invention.

[0077] In order to more clearly understand the present technology, preferred embodiments will be described with reference to the following drawings and examples. BRIEF DESCRIPTION OF THE DRAWINGS

[0078] Figure 1 A representative schematic diagram of the 3D bioprinting process.

[0079] Figure 2 Shown are (a) UV analysis; and (b) quantitative analysis of CRGDS conjugation analysis of CRGDS modified 4-arm PEG-Mal by 1H NMR.

[0080] Figure 3 Shown are the results of (a) frequency; (b) strain; (c) stiffness; and (d) viscosity rheological studies of hydrogels prepared from 4-arm PEG-Mal hydrogels with 2.5 mM RGD (10 wt %) and cross-linked with PEG dithiol and MMP-2 responsive dicysteine ​​peptide (mixed at 50:50 thiol molar concentration).

[0081] Figure 4 Shown are the results of stiffness rheological studies of (a) blank 4-arm PEG-Mal hydrogel cross-linked with PEG-bisthiol at 7.5 wt % and (b) PEG-tripeptide hydrogel cross-linked with a MMP-responsive bis-cysteine ​​peptide activator. DETAILED DESCRIPTION

[0082] This technology involves 3D printed hydrogels. 3D printed hydrogels are able to support cell viability for a long time. The hydrogels of this technology are prepared by 3D printing polymer bio-inks and activators, which are biocompatible and quickly form hydrogels when printed, allowing high-throughput production and analysis of 3D cell structures.

[0083] In particular, the inventors have found that covalently crosslinking maleimide-containing polymers using dithiol-containing crosslinkers allows rapid formation of uniform hydrogels via a biocompatible crosslinking pathway under physiological conditions without the aid of any co-reactants and without generating any toxic byproducts. Thus, the 3D printed hydrogels of the present technology are formed by combining a maleimide-containing polymer with an activator comprising a dithiol crosslinker having at least two thiol functional groups.

[0084] Polymer Bioink

[0085] The polymer bio-ink of the present technology comprises a maleimide-containing polymer or a composition comprising two or more maleimide-containing polymers. The maleimide-containing polymer can be any polymer containing maleimide reactive groups that forms a hydrogel. Polymers containing free maleimide groups can also be present in the hydrogel.

[0086] Maleimide-containing polymers having various molecular weights, molecular structures, molecular distributions, and functionalities can be used in polymer bio-inks. For example, the molecular weight of the maleimide-containing polymer can range from about 1 kDa to about 10,000 kDa, or from about 5 kDa to about 10,000 kDa, or from about 5 kDa to about 5,000 kDa, or from about 5 kDa to about 1,000 kDa, or from about 10 kDa to about 1,000 kDa, or from about 20 kDa to about 1,000 kDa, or from about 10 kDa to about 500 kDa. The maleimide-containing polymer can have any suitable molecular structure, for example, linear, block, branched, star, ring, comb or brush polymers, or any combination thereof. Molecular distribution refers to the distribution of monomer units along the polymer backbone, and can include homo distribution, block distribution, statistical distribution, random distribution, or multi-block distribution, or any combination thereof. Functionality (ie, type of monomer) may include, but is not limited to, hydroxyl, amine, thiol carboxylic acid, olefin, alkyne, polycyclic carbocycle, etc. A polymer may contain one functionality or two or more functionalities (ie, a copolymer).

[0087] In one embodiment, the maleimide-containing polymer is biocompatible.

[0088] The maleimide-containing polymer is prepared by adding two or more maleimide reactive groups to the polymer. The two or more maleimide groups can be added to the polymer by any suitable method known in the art such as carbodiimide coupling, Steglich esterification, and coupling reaction of mercaptan maleimide with excess bismaleimide molecules. In addition or alternatively, commercially available maleimide-containing polymers can be used.

[0089] Non-limiting examples of maleimide-containing polymers suitable for use in polymer bio-inks in the present technology include: maleimide-containing polysaccharides, such as polymers containing fructose, sucrose or glucose monomers; synthetic polymers, such as poly(ethylene glycol) (PEG) maleimide, poly(hydroxyethyl methacrylate) (PHEMA) maleimide, poly(ε-caprolactone) (PCL) maleimide, poly(vinyl alcohol) (PVA) maleimide, poly(vinyl pyrrolidone) (PVP) maleimide, poly(N-isopropylacrylamide) (NIPAAM) maleimide, poly(propylene fumarate) (PPF) maleimide, poly(ethyleneimine) (PEI) maleimide, poly(3-methacrylamidopropyl) trimethylammonium (PMAE) maleimide, poly(ethyleneimine) (PEI) maleimide, poly(3-methacrylamidopropyl) trimethylammonium (PMAE) maleimide, poly(ethyleneimine) (PEI) maleimide, poly(ethyleneimine) (PEI) maleimide, poly(ethyleneimide) trimethylammonium (PEM ... maleimide, or derivatives thereof; maleimide-containing biopolymers such as gelatin maleimide, cellulose maleimide, hyaluronic acid maleimide and alginate maleimide; and maleimide-containing nucleobase polymers (i.e., polymers of adenine, thymine, guanine and / or cytosine repeating units containing maleimide); or any combination thereof.

[0090] PEG is a particularly attractive material for preparing synthetic hydrogels as ECM mimics because it is commercially available, inert, non-toxic in biological applications, and has multiple uses for various chemical modifications. Further, PEG-based polymer bio-inks can have relatively low viscosities due to the low molecular weight of the PEG polymer precursor, making them particularly suitable for on-demand titration bioprinting. Therefore, in one embodiment, the maleimide-containing polymer is a polyethylene glycol (PEG) polymer (PEG-maleimide) containing at least two maleimide reactive groups. PEG-maleimide can have any suitable molecular structure, including but not limited to 3-arm PEG-maleimide, 4-arm PEG-maleimide, PEG block copolymers with at least two maleimide groups, or any combination thereof. The PEG group can have any suitable molecular weight. For example, the molecular mass of the PEG group can range from about 1 kDa to about 50 kDa, or about 1 kDa to about 40 kDa, or about 1 kDa to about 30 kDa, or about 5 kDa to about 30 kDa, or about 5 kDa to about 20 kDa, or about 5 kDa to about 10 kDa, or about 10 kDa to about 20 kDa. In one embodiment, the molecular mass of the PEG group is about 5 kDa, or about 10 kDa, or about 20 kDa.

[0091] The term "3-arm PEG maleimide" refers to a polymeric compound having the following structure (n=38-3,788):

[0092]

[0093] The term "4-arm PEG maleimide" refers to a polymeric compound having the following structure (n=28-2,841):

[0094]

[0095] The performance of maleimide-containing polymers can be tailored for specific applications by partially modifying the maleimide groups with one or more functional groups or other moieties. Partial modification means that at least one, preferably at least two maleimide groups remain intact to be cross-linked with a dithiol-containing cross-linking agent. Therefore, if a bioactive molecule is added to a maleimide-containing polymer, the maleimide-containing polymer comprises at least two and typically at least three maleimide groups. This method allows the reproducibility and modularity of the polymer to be maintained while introducing relevant biological properties into 3D printed hydrogels. Therefore, in one embodiment, the maleimide groups of the maleimide-containing polymer can be partially modified with one or more bioactive molecules.

[0096] The polymer bio-ink of the present technology can be prepared as an aqueous solution containing a maleimide-containing polymer in any suitable formulation known in the art. For example, the polymer bio-ink can be prepared as an aqueous formulation containing at least one maleimide-containing polymer and optionally one or more bioactive molecules. For example, the aqueous formulation can be a solution containing a maleimide-containing polymer in a pH buffer solution or a cell culture medium. In some embodiments, the polymer bio-ink may contain two maleimide-containing polymers in any ratio, for example, a ratio of about 10:1 to about 1:10, for example, about 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9 or 1:10.

[0097] In one embodiment, the polymer bio-ink may be provided in the form of an aqueous solution containing a maleimide-containing polymer. Generally, the polymer bio-ink can be prepared by dissolving the maleimide-containing polymer in a solution, preferably a cell culture medium. In some embodiments, the polymer bio-ink may contain a mixture of two or more maleimide-containing polymers. The polymer bio-ink may contain any suitable concentration of maleimide-containing polymers in the solution. For example, the concentration of the maleimide-containing polymer in the polymer bio-ink solution may range from about 1wt% to 50wt%, or about 1% to 40wt%, or about 1wt% to 30wt%, about 5wt% to 20wt%, about 5wt% to 15wt%, or about 10wt% to 20wt%. The polymer bio-ink may include one or more bioactive molecules covalently bound to the maleimide-containing polymer. In addition or alternatively, the polymer bio-ink may include one or more free bioactive molecules in the solution. The concentration of the bioactive molecules in the polymer bio-ink may range from about 0.1 mM to 10 mM, about 0.5 mM to 10 mM, about 1 mM to 10 mM, about 1 mM to 5 mM, about 2 mM to 5 mM, or about 2 mM to 3 mM.

[0098] In one embodiment, the polymer bio-ink is prepared as a sterile solution. Suitable methods for preparing a sterile solution or sterilizing the polymer bio-ink are well known to those skilled in the art.

[0099] In one embodiment, the polymer bio-ink is biocompatible.

[0100] Activator

[0101] The activator of the present technology includes a dithiol crosslinking agent. The dithiol crosslinking agent can be any compound containing at least two thiol functional groups, also referred to herein as dithiol. Preferably, the thiol functional group is a terminal thiol functional group.

[0102] In one embodiment, the dithiol-containing cross-linker is biocompatible.

[0103] In one embodiment, the dithiol-containing crosslinking agent can be a dithiol-containing polymer, preferably, a synthetic polymer containing terminal dithiol. Suitable synthetic polymers containing dithiol include but are not limited to PEG-dithiol, poly (N-isopropylacrylamide)-dithiol (NIPAAM-dithiol), poly (acrylic acid)-dithiol, poly (methacrylic acid)-dithiol, poly (styrene sulfonate)-dithiol, poly (amide)-dithiol, or any combination thereof. In addition, the dithiol-containing crosslinking agent can be a dithiol-containing biopolymer, preferably, a terminal dithiol-containing biopolymer. Suitable dithiol-containing biopolymers include but are not limited to thiol-gelatin (e.g., derived from cattle, pigs and cold fish), thiol-hyaluronic acid (e.g., derived from Streptococcus equi, cattle and human umbilical cord), or any combination thereof.

[0104] In one embodiment, the dithiol-containing cross-linking agent is PEG dithiol. PEG dithiol can have any suitable molecular structure, including but not limited to linear, branched and star-shaped PEF structures, etc. In one embodiment, PEG dithiol is a linear PEG dithiol. The molecular mass of the PEG group can be changed, for example, the molecular mass of the PEG group can range from about 1 kDa to about 50 kDa, or about 1 kDa to about 40 kDa, or about 1 kDa to about 30 kDa, or about 5 kDa to about 30 kDa, or about 5 kDa to about 20 kDa, or about 5 kDa to about 10 kDa, or about 10 kDa to about 20 kDa. In one embodiment, the molecular mass of the PEG group is about 5 kDa, or about 10 kDa, or about 20 kDa.

[0105] Examples of linear PEG dithiols have the following structures (n=11-1,136):

[0106]

[0107] In some embodiments, the dithiol-containing crosslinking agent can be a dithiol-containing small molecule. Suitable dithiol-containing molecules include, but are not limited to, dithiothreitol (DTT) (used with or without sodium borate or boron), or any combination thereof. In other embodiments, the dithiol-containing crosslinking agent can be a dithiol-containing short-chain peptide having at least two cysteine ​​amino acid groups, preferably a terminal cysteine ​​group (i.e., an amino acid sequence with thiols attached to the side). Suitable dithiol-containing short-chain peptides with two cysteine ​​amino acid groups attached to the side include, but are not limited to, inert short-chain peptide sequences, enzyme-reactive short-chain peptides (e.g., MMP-responsive, serine-reactive, cysteine-reactive, aspartic acid-reactive, glutamate-reactive, cysteine-reactive or trypsin-reactive peptide sequences), or any combination thereof.

[0108] In one embodiment, the dithiol-containing cross-linking agent is a dithiol-containing bioactive molecule. For example, the dithiol-containing short-chain peptide can be an MMP-responsive dicysteine ​​peptide. For example, the MMP-responsive dicysteine ​​peptide can be an MMP-2 responsive dicysteine ​​peptide (e.g., GCIPVSLRSGCG), an MMP-1, -2, -3, -7, 8 and -9 responsive dicysteine ​​peptide (e.g., GCRDGPQGIWGQDRCG), an MMP-15 responsive thiolated peptide (e.g., GCRDEAPLKQDRCG) or an MMP-1, -2, 3, 7, -8, -9, -12, 13 and -14 responsive dicysteine ​​peptide (e.g., GCRDPLGLDRCG).

[0109] The activator may include a combination of two or more types of dithiol-containing crosslinking agents in any ratio. For example, the activator may include a combination of two types of dithiol-containing crosslinking agents in a ratio of about 10:1 to about 1:10, such as about 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, or 1:10.

[0110] In one embodiment, the activator may be in the form of an aqueous solution comprising a dithiol crosslinker. The aqueous solution may be a cell culture medium. In some embodiments, the activator may comprise a mixture of two or more thiol crosslinkers. The activator may contain any suitable concentration of a dithiol crosslinker. The activator may contain any suitable concentration of a thiol crosslinker in the solution. In a preferred embodiment, the concentration of the dithiol crosslinker in the activator is equal to or less than the concentration of the maleimide-containing polymer in the supplementary polymer bio-ink. The ratio of the maleimide-containing polymer to the dithiol crosslinker ranges from about 10:1 to 1:1, about 9:1 to 1:1, about 8:1 to 1:1, about 7:1 to 1:1, about 6:1 to 1:1, about 5:1 to 1:1, about 4:1 to 1:1, about 3:1 to 1:1, or about 2:1 to 1:1. The dithiol crosslinker may comprise a bioactive molecule, or it may comprise one or more bioactive molecules covalently bound thereto. Additionally or alternatively, the activator may include one or more free bioactive molecules in the solution. The concentration of the bioactive molecules in the activator may range from about 0.1 mM to 10 mM, about 0.5 mM to 10 mM, about 1 mM to 10 mM, about 1 mM to 5 mM, about 2 mM to 5 mM, or about 2 mM to 3 mM.

[0111] In one embodiment, the activator is a sterile solution. Suitable methods for preparing sterile solutions or methods for sterilizing activator solutions are well known to those skilled in the art.

[0112] The formulation of the activator can be the same as that of the polymer bio-ink, or different. In a preferred embodiment, the formulations for the polymer bio-ink and the activator are the same.

[0113] In one embodiment, the activating agent is biocompatible.

[0114] 3D printing hydrogel

[0115] The 3D printed hydrogel of the present technology comprises a maleimide-containing polymer cross-linked using a dithiol-containing cross-linker. In one embodiment, the 3D printed hydrogel contains cells.

[0116] In one embodiment, the 3D printed hydrogel is prepared by 3D printing a polymer bio-ink comprising a maleimide-containing polymer and an activator comprising a dithiol-containing cross-linker.

[0117] To be suitable for 3D printing, hydrogels should form rapidly. However, the rapid formation of hydrogels used in the prior art often results in the formation of irregular hydrogels. Current methods for controlling the rate of crosslinking agents and generating UV radiation in 3D printing include the use of external driving forces, such as UV radiation and co-reactants or catalysts. These external drivers do not participate in the formation of the hydrogel, but can assist in the formation of the hydrogel and have an effect on the cellular and biological characteristics of cells encapsulated in the hydrogel. In particular, photochemical crosslinking reactions involving the use of UV radiation may include the use of a free radical source that must be removed from the product so that it does not interact with the cells in the hydrogel.

[0118] Surprisingly, the present inventors have discovered that the formation of uniform hydrogels capable of supporting high density, high viability cells can be achieved by reacting a maleimide-containing polymer with a dithiol-containing crosslinker. Under physiological conditions, the maleimide groups react rapidly and simultaneously with the thiol. Since the reaction does not require any external driving force, it is particularly suitable for 3D bioprinting for in vitro analysis because it eliminates the need for potentially cytotoxic co-reactants, free radical initiators, or UV irradiation. In addition, no harmful or cytotoxic byproducts are produced, thereby allowing in situ printing of cells without the production of harmful byproducts.

[0119] When the polymer bio-ink is in contact with the activator, a cross-linking reaction can be rapidly performed between the maleimide-containing polymers using a dithiol-containing cross-linking agent, thereby allowing for rapid formation of a 3D printed hydrogel. Thus, in some embodiments, the hydrogel is formed within 30 minutes or less from the time the polymer bio-ink and activator are printed. For example, the hydrogel can be formed within 30 minutes or less, or 20 minutes or less, or 10 minutes or less, or 1 minute or less, or 30 seconds or less, or 10 seconds or less, or 1 second or less from the time the polymer bio-ink and activator are printed. Various factors, such as size, shape, and composition, can affect the rate at which a 3D printed hydrogel is formed.

[0120] An exemplary reaction between a maleimide-containing polymer and a dithiol-containing crosslinker is shown in the following reaction formula 1. The reaction includes a nucleophilic (Machael) addition of a thiol group on the dithiol-containing crosslinker (1) to an olefin functional group of the maleimide moiety on the maleimide-containing polymer (2) to produce a 3-substituted succinimide group under aqueous conditions (e.g., in a cell culture medium). The reaction is particularly useful for 3D bioprinting for in vitro analysis because it does not require potentially cytotoxic co-reactants, free radical initiators, or UV irradiation. Further, when the maleimide-containing polymer and the dithiol crosslinker are mixed under physiological conditions (e.g., pH of about 6.5 to 7.5, preferably pH 7.4), covalent crosslinking occurs rapidly and simultaneously to produce a crosslinked polymer (3).

[0121]

[0122] Reaction 1

[0123] In one embodiment, the pH of the polymer bio-ink, the activator, or both is adjusted to a physiological pH (eg, about 6.5-7.5, preferably about pH 7.4) using a suitable base prior to 3D printing. Suitable bases are readily apparent to those of ordinary skill in the art.

[0124] In one embodiment, the base is NaOH.

[0125] The inventors have found that using NaOH to adjust the pH of the polymer bio-ink, the activator can accelerate gelation during 3D printing, thereby allowing rapid formation of 3D printed hydrogels (e.g., less than about 1 second). Further, the inventors have found that the presence of NaOH can reduce the aggregation of cells in the polymer bio-ink, the activator, or both, thereby allowing high concentrations of cells to be dispersed in the solution for 3D printing through a small nozzle opening.

[0126] In one embodiment, the molar concentration of the maleimide-containing polymer is greater than the molar concentration of the biothiol-containing cross-linking agent, thereby consuming the dithiol-containing cross-linking agent. The resulting hydrogel may contain cross-linked products and excess maleimide-containing polymer (if any), but does not contain any additional unwanted by-products. For example, the molar ratio of maleimide-containing polymer to dithiol-containing cross-linking agent can range from about 10:1 to 2:1, about 9:1 to 2:1, about 8:1 to 2:1, about 7:1 to 2:1, about 6:1 to 2:1, about 5:1 to 2:1, about 4:1 to 2:1, about 3:1 to 2:1.

[0127] Preferably, for the formation of a hydrogel, the number of thiol groups in the dithiol crosslinker is greater than about 60% of the number of maleimide groups in the maleimide-containing polymer. For example, the number of thiol groups in the dithiol crosslinker is greater than about 60% of the number of maleimide groups in the maleimide-containing polymer. The number of thiol groups in the dithiol crosslinker can be about 60% or 70% or 80% or 90% or 100% or 200% or more relative to the number of maleimide groups in the maleimide-containing polymer. In some embodiments, the number of thiol groups in the dithiol crosslinker is the same as the number of maleimide groups in the maleimide-containing polymer (i.e., 100%).

[0128] Because the polymer bio-inks and activators disclosed herein can be used to perform a large number of assays, the materials used to prepare the polymer bio-inks and activators are preferably readily available in bulk commercially, or are easily prepared from such commercially available materials.

[0129] A typical method for preparing the 3D printing technology of the present technology may include the following steps:

[0130] Providing a polymer bio-ink, the polymer bio-ink comprising a maleimide-containing polymer;

[0131] providing an activator, the activator comprising a dithiol-containing cross-linking agent; and

[0132] 3D printed polymer bio-ink and activator to form 3D printed hydrogel.

[0133] In one embodiment, the method further comprises providing cells, so that a 3D printed hydrogel containing cells is formed by 3D printing bio-ink, activating agent and cells.

[0134] In one embodiment, the cells are suspended in the hydrogel. The cells may be provided in the polymer bio-ink, the activator, or both, or in another culture medium. The cells may be suspended in a portion (or multiple portions) of the hydrogel, or they may be suspended substantially uniformly throughout the hydrogel.

[0135] In one embodiment, the cells are provided in a cell culture medium. The cell culture medium may be included in the polymer bio-ink, the activator, or may be provided separately from the polymer bio-ink and the activator. For example, the cell culture medium may be suspended between the 3D printed hydrogel layers formed by the polymer bio-ink and the activator, or it may be deposited on the surface of the hydrogel.

[0136] In one embodiment, the 3D printed hydrogel further contains a bioactive molecule. The bioactive molecule can be provided in the polymer bio-ink or the activator or both. The bioactive molecule can be freely suspended in the polymer bio-ink or the activator or both, or it can be combined with a maleimide-containing polymer and / or a dithiol-containing cross-linking agent.

[0137] In one embodiment, the 3D printing process is performed in a substantially sterile environment.

[0138] Bioactive molecules

[0139] The 3D printed hydrogels of the present technology can be modified by one or more bioactive molecules to introduce certain biological characteristics. For example, the biological characteristics of the 3D printed hydrogel can be modified by adding proteins, peptides (such as MMP responsive peptides), chemical attractants, growth factors, organic dyes, fluorescent dyes, drugs, therapeutic agents, antibodies, small molecule inhibitors, kinase inhibitors, phosphatase inhibitors, antigens, pathogens, platelets, cytokines, nutrients (such as monosaccharides and polysaccharides), conditioned medium, antibiotics, antiviral drugs, RNA and related variants (such as siRNA, mRNA), etc. One or more bioactive molecules can be added to the 3D printed hydrogel by reacting with a maleimide-containing polymer, a dithiol-containing crosslinker, or any combination thereof. Nanoparticles can also be added to the 3D printed hydrogel.

[0140] In one embodiment, the bioactive molecule is a short-chain peptide (e.g., a cysteine ​​(C) amino acid containing Arg-Gly-Asp (RGD) at the N or C terminus), a growth factor (e.g., VEGF), a protein (e.g., laminin, collagen), or a chemoattractant (e.g., stromal cell-derived factor-1 (CXCL12)), or any combination thereof. Other suitable bioactive molecules are well known to those skilled in the art.

[0141] In some embodiments, one or more bioactive molecules can be added to the 3D printed hydrogel by adding free bioactive molecules to the polymer bio-ink, the activator, or both. The polymer bio-ink, the activator, or both can include cell culture media.

[0142] In one embodiment, the bioactive molecule can be combined with a maleimide-containing polymer. The bioactive molecule can be introduced into the maleimide-containing polymer to form a covalent bond by reacting the maleimide group with the bioactive molecule. For example, a covalent bond can be formed by a Machael addition reaction between a thiol and a vinyl-containing bioactive molecule (e.g., in an aqueous medium), a Schiff base reaction between an amino group and an aldehyde group, a Diels-Alder reaction, click chemistry, an aminolysis reaction to an active ester group or an enzyme cross-linking. Thiol groups are abundant in many bioactive molecules, and therefore, bioactive molecules can be added to maleimide-containing polymers by affinity (Machael) addition of thiol groups to the olefin groups of maleimide groups to produce 3-substituted succinimide groups. Depending on the conditions and molar ratios of the reactants used, the resulting compound will have at least one maleimide group that can be modified to a biologically active molecule containing 3 substituted succinimide groups, thereby leaving at least one, preferably at least two, maleimide groups intact. One skilled in the art will be able to determine the appropriate conditions (e.g., molar ratios of reactants) to control the reaction, thereby ensuring that at least one, preferably at least two, maleimide groups remain intact.

[0143] In a typical method of adding a thiol-containing bioactive molecule to a maleimide-containing polymer, the bioactive molecule and the maleimide-containing polymer are mixed in an aqueous solution (e.g., a buffer or cell culture medium) at room temperature in a molar ratio of maleimide polymer to bioactive molecule (e.g., 3:1, 4:1, or 5:1). The completion of the reaction is monitored, for example, by an Ellman assay to confirm that no free thiol groups are present. A typical reaction time is about 30 minutes. After the reaction is complete, if necessary, a suitable base (e.g., NaOH) may be added to adjust the pH of the solution to physiological pH (about 7.4). Suitable bases for adjusting the pH to physiological pH will be apparent to those skilled in the art. The resulting modified maleimide-containing polymer solution may be used without separation or purification.

[0144] In one embodiment, NaOH is used to adjust the pH of the polymer bio-ink or activator solution containing biomolecules to a physiological pH (e.g., about 6.5-7.5, preferably pH 7.4). Using NaOH to adjust the pH of the polymer bio-ink or activator solution allows for rapid polymerization during subsequent 3D printing, thereby accelerating the formation of the hydrogel (e.g., less than 1 second). Further, the use of NaOH can reduce the aggregation of cells in the polymer bio-ink, activator, or both, thereby allowing a high concentration of cells to be dispersed in the solution for 3D printing through a small nozzle opening.

[0145] Examples of 4-arm PEG-maleimide modified with RGD moieties (4-arm PEG-maleimide-RGD) have the following structures (n=28-2,841), prepared by reacting 4-arm PEG-maleimide with CRGDS at a 4:1 molar ratio:

[0146]

[0147] Examples of 4-arm PEG-maleimide modified with VEGF moiety (4-arm PEG-maleimide-VEGF) have the following structures (n=28-2,841), prepared by reacting 4-arm PEG-maleimide with VEGF at a 4:1 molar ratio:

[0148]

[0149] In some embodiments, a bioactive molecule, such as CRGDS, CIKVAV, VEGF, and a C-terminal unpaired cysteine ​​and / or MMP responsive peptide (e.g., GCIPVSLRSGCG, GCRDGPQGIWGQDRCG, GCRDPLGLDRCG, or GCRDEAPLKQDRCG) is added to a 3D printed hydrogel to introduce biofunctionality. For example, cell attachment properties can be introduced by adding CRGDS or CIKVAV cell adhesion motifs, angiogenesis can be promoted by adding VEGF, and cell motility can be promoted by adding MMP responsive peptide crosslinkers. GCIPVSLRSGCG is particularly suitable for use as a dithiol-containing crosslinker in a crosslinker, but can additionally or alternatively be covalently linked to a maleimide-containing polymer, a dithiol-containing crosslinker, or both, or added as a free bioactive molecule to a polymer bio-ink, an activator, or both.

[0150] The bioactive molecule can be present in the 3D printed hydrogel at any suitable concentration to achieve the desired biological characteristics. For example, the bioactive molecule can be present in the 3D printed hydrogel at a concentration of about 1 nM to 100 μM, about 1 nM to 50 μM, about 5 nM to 50 μM, about 10 nM to 50 μM, about 50 nM to 50 μM, about 100 nM to 50 μM, about 100 nM to 1 μM, or about 500 nM to 1 μM.

[0151] cell

[0152] Cells can be added to the 3D printed hydrogels of the present technology. Cell culture media can also be added to the hydrogel to maintain cell viability or promote growth and cell division. Cells and / or cell culture media can be added to the hydrogel by adding them to the polymer bio-ink or the activator or both.

[0153] In one embodiment, the cells are provided in a polymer bio-ink, an activator, a polymer bio-ink or an activator, or in a separate medium.

[0154] The polymer bio-ink and / or activator may include a cell culture medium. The cell culture medium may be selected from any suitable culture medium compatible with the cells and maintaining cell viability during 3D printing. For example, the cell culture medium may be a solution comprising water (e.g., sterilized MilliQ water), a buffer and a cell culture medium. Suitable buffers include, but are not limited to, phosphate buffered saline (PBS), 2-[4-(2-hydroxyethyl)piperazine-1-yl]ethanesulfonic acid (HEPES) and 2-(cyclohexylamino)ethanesulfonic acid (CHES), or any combination thereof. Non-limiting examples of suitable cell culture media include Dulbecco's modified Eagle medium (DMEM), minimum essential medium (MEM), Iscove's modified Dulbecco's medium (IMDM), culture medium 199, Ham's F10, Ham's F12, McCoy's 5A and Roswell Park Memorial Institute (RPMI) culture medium.

[0155] In some embodiments, the cell culture medium may further include a reducing agent (e.g., 2-thiolethanol or tris(2-carboxyethyl)phosphine (TCEP)), a stabilizer (e.g., or PVP) and / or growth supplements (e.g., L-glutamine or hydrocortisone). Non-limiting examples of suitable growth supplements include fetal calf serum (FCS), epidermal growth factor (EGF), basic fibroblast growth factor (FBF), fibroblast growth factor (FBF), endothelial cell growth factor (ECGF), insulin-like growth factor 1 (IGF-1), and platelet-derived growth factor (PDGF). For example, a reducing agent can prevent the formation of disulfide bonds between free thiol groups in a cross-linking agent. For example, a stabilizer can be used to prevent cells from precipitating out of a cell culture medium. If necessary, a suitable base can be used to adjust the pH of the cell culture medium to a physiological pH of about 7.4. In one embodiment, sodium hydroxide (NaOH) is used as a base to neutralize or control the pH of the cell culture medium because it does not promote cell aggregation.

[0156] The harvested cells can be resuspended in the polymer bio-ink or the activator, or both, at a selected cell concentration. The concentration of cells in the polymer bio-ink and / or the activator ranges from approximately 1×10 5 Up to about 5×10 8 cells / mL, or approximately 1×10 5 To about 1×10 8 cells / mL, or approximately 1×105 To about 1×10 7 cells / mL, 5×10 5 To about 1×10 7 cells / mL, or approximately 5×10 5 Up to about 5×10 6 cells / mL, or approximately 1×10 6 Up to about 5×10 6 In one embodiment, the cells are present in a concentration of approximately 4×10 6 Up to about 5×10 6 The cells are suspended in polymer bioink and / or activating agents or cell culture medium at a concentration of 10 cells / mL.

[0157] Any suitable cells can be used with the polymer bio-ink and activator of the present technology. For example, suitable cells can include, but are not limited to, adherent cells, such as mammalian hepatocytes, gastrointestinal cells, pancreatic cells, kidney cells, lung cells, tracheal cells, vascular cells, skeletal muscle cells, cardiomyocytes, skin cells, smooth muscle cells, connective tissue cells, corneal cells, urogenital cells, mammary cells, germ cells, endothelial cells, epithelial cells, fibroblasts, neural cells, Schwann cells, adipocytes, bone cells, bone marrow cells, chondrocytes, pericytes, mesothelial cells, endocrine tissue-derived cells, stromal cells, stem cells, progenitor cells, lymphocytes, blood cells, endoderm-derived cells, ectoderm-derived cells, mesoderm-derived cells, or any combination thereof.

[0158] Other suitable cell types may include other eukaryotic cells (eg, Chinese hamster ovary), bacteria (eg, Helicobacter pylori), fungi (eg, Penicillium chrysogenum), and yeast (eg, Saccharomyces cerevisiae).

[0159] The 3D printed hydrogel may contain at least about 100, or about 1000, or about 5000, or about 10000, or about 50,000, or about 100,000, or about 150,000, or about 200,000, or about 250,000, or about 300,000, or about 350,000, or about 400,000, or about 450,000, or about 500,000 or more cells. Those skilled in the art will appreciate that other numbers of cells may be used.

[0160] In some embodiments, the method further includes cultivating the cells suspended in the hydrogel under conditions that allow cell growth or maintenance. In some embodiments, the cells can be suspended in the hydrogel under conditions that allow stem cell differentiation. Cultivation can be performed at any suitable temperature and conditions. For example, cultivation suitable for cell growth, maintenance or differentiation can be performed at about 37° C. and about 5% CO2 for at least 24 hours. It should be understood that cultivation can be performed at any temperature and duration that allows cell growth, maintenance or differentiation of the cell type in the hydrogel.

[0161] In other embodiments, the method further comprises culturing the cells suspended in the hydrogel under conditions that are not suitable for cell growth. For example, the culturing may be carried out under hypoxic conditions, in a serum-free environment to starve the cells, in an acidic or alkaline environment, under applied external pressure, in the presence of an electric field, under continuous oscillation, or any combination thereof. Other suitable conditions for simulating certain biological conditions are well known to those skilled in the art.

[0162] 3D bioprinting

[0163] The polymer bio-ink and activator of the present technology are suitable for drop-on-demand (DOD) bioprinting, where bioprinting is based on the generation of discrete droplets of polymer bio-ink and activator, and can include thermal inkjet, piezoelectric inkjet, and microvalve-based bioprinting, etc. As with any other drop-on-demand printing technology, the polymer bio-ink and activator must be liquid in the bioprinter cartridge. In addition, the polymer bio-ink and activator should be made of biocompatible materials to maintain high cell viability when stored in the bioprinting cartridge.

[0164] DOD bioprinting for 3D assays includes repeatedly depositing a drop of polymer bio-ink and activator on a substrate, the size and position of which are determined by the bioprinting software. Therefore, in one embodiment, 3D bioprinting is performed using a 3D bioprinter capable of forming and depositing droplets. The bioprinter may have at least a fluid reservoir for polymer bio-ink, activator and cleaning solution, a 3-axis motion console, a drop-on-demand droplet dispensing system, and a pressure regulator for controlling the pressure in the fluid reservoir. The droplet dispensing system and the 3-axis console may be placed in a sterile room such as a laminar flow cabinet. The printing platform may include adapters suitable for printing onto a variety of substrates such as microplates and culture dishes. The printing platform can be heated to approximately 37°C to assist cell proliferation.

[0165] The 3D bioprinter can be controlled by a computer with software that defines the printing format.

[0166] The 3D bioprinter can be configured to print (deposit) droplets of polymer bio-ink and activator in a manner that allows for cell integrity, viability, or functionality. It should be understood that the deposition of polymer bio-ink and activator can be performed in any order. A drop of polymer bio-ink can be applied to a substrate, followed by a drop of activator to form a hydrogel droplet, or a drop of activator can be applied to a substrate, followed by a drop of polymer bio-ink to form a hydrogel droplet.

[0167] The hydrogel formed by the present technology process comprises a substantially uniform 3D structure. When the hydrogel comprises cells, the cells may be substantially uniformly distributed throughout the hydrogel, or they may be suspended within the hydrogel portion of the hydrogel. The cells may be deposited at one or more selected locations in the hydrogel.

[0168] Printing substrate is a biocompatible consumable for sealing and cultivating printed hydrogel structures. The substrate can be selected from any suitable container for accommodating, maintaining or growing cells. Examples include microtiter plates with different pore structures (6, 24, 48 and 96 holes), microtiter plates with coverslip bottoms with different pore structures (6, 24, 48 and 96 holes), fluorescent culture dishes of various sizes, chamber slides, coverslips or microscope slides or culture dishes with different pore structures (1, 2, 4, 8 and 16). In some embodiments, 3D bioprinting process is carried out to form multiple 3D tissue culture models on a matrix. For example, 96-well microtiter plates are suitable substrates that can be used for multicellular analysis. Other suitable containers are well known to those skilled in the art.

[0169] The 3D structure analyzed can be designed using bioprinter software. Suitable bioprinters and bioprinter software are well known to those skilled in the art. For example, for bioprinting in a 96-well plate, the bioprinting software can be configured to repeatedly deposit droplets in wells in a layer of a selected diameter.

[0170] The polymer bio-ink and activator react rapidly during printing to form a hydrogel, thereby allowing rapid, high-throughput production of 3D structures and analysis. In one embodiment, the polymer bio-ink and activator of the present technology form a hydrogel within seconds of mixing (i.e., during printing). For example, the hydrogel can be formed within 5 seconds of mixing, preferably within 4, 3, 2, or 1 second of mixing.

[0171] The polymer bio-inks and activators of the present technology can be used with any suitable DOD bio-printing system. The inventors recently developed a DOD bio-printing system specifically for bio-printing of 3D in vitro analysis. More specifically, the bio-printer is capable of printing polymer bio-inks and activators at speeds of up to 200 cP, and is capable of printing cells at speeds of up to 500 million cells / mL with a cell viability of greater than 95%. The developed system has been successfully used to bio-print 3D spheroid analysis in a high-throughput manner. Therefore, the bio-inks of the present technology are particularly useful for 3D cell printing using a 3D bio-printing system developed by the inventors.

[0172] The rapid gelation properties of the hydrogels of the present technology, combined with the novel printing logic of the developed bioprinter, enable the bioprinter to rapidly print complex 3D analyses in a 96-well format. For example, bioprinting of 3D analyses in a 96-well plate can be achieved in less than about 1 hour, preferably less than about 30 minutes (e.g., about 25 minutes or about 20 minutes or about 15 minutes or less).

[0173] The polymer bio-ink and activator can be loaded into a separate sterilized cartridge immediately before printing, or stored in the cartridge. If the cell bio-ink is stored in the cartridge, the cartridge is preferably stored at 4°C for future use. The polymer bio-ink and activator of the present technology can support cell viability for a long time before printing. For example, cells can remain viable in the polymer bio-ink and activator for at least about 2 hours before printing. In some embodiments, the polymer bio-ink and activator of the present technology can be stored at -20°C for at least 6 months without substantially affecting cell viability. Similarly, the 3D printed hydrogel of the present technology can support cell viability for a longer period of time after printing. For example, cells can remain viable in the 3D printed hydrogel for at least about 21 days.

[0174] When ready for use, the cartridge can be connected to a cleaned bioprinter. Cleaning of the cartridge and / or bioprinter (including fluid lines, valves, and nozzles) can be achieved by any suitable method known in the art, for example, by wiping with ethanol (70 v / v% in water), air drying, and placing in a biosafety cabinet. Preferably, the bioprinter is rinsed with tissue culture medium after cleaning and before printing.

[0175] application

[0176] The 3D printed hydrogels of the present technology can have various in vitro applications. In one example, the 3D printed hydrogels of the present technology can be used to prepare analyses for examining biological phenotypes, including but not limited to cell motility, cell migration, cell invasion, transendothelial migration, epithelial-mesenchymal transition, mesenchymal-epithelial transition, spheroid formation and growth, cell invasion differentiation (e.g., stem cell differentiation, cell differentiation marker monitoring), cell death (e.g., apoptosis; cell necrosis), cell autophagy, cell proliferation, cell metabolism, protein turnover, protein distribution and localization, cell signaling and downstream events, drug efficacy, drug pharmacodynamics, drug action mechanism, drug receptor-mediated transport, drug internalization mechanism, biomarker evaluation, cell-cell connection, cell-cell signaling and downstream events, cell morphology, cell adhesion, gene expression , protein expression, cell homing, cell cycle regulation, cytokine release, insulin production, protein secretion and intracellular trafficking, receptor-ligand binding, antibody binding, antibody specificity, protein phosphorylation, proteomic function, enzyme function (e.g., enzyme inhibition), immunomodulation, clonogenicity, oxidative stress, protein folding, cytoskeleton, organelle morphology and function (e.g., mitochondria, chloroplasts, peroxisomes, secretory vesicles, vacuoles, ribosomes, nuclei, lysosomes, cilia, endoplasmic reticulum, Golgi apparatus), membrane transport, hypoxia, angiogenesis, wound healing, neurite outgrowth or formation, kinase function, phosphatase function, lamellipodia formation and dynamics, focal contact / adhesion formation, kinetic signaling, cell sensing, and mechanotransduction.

[0177] The 3D printed hydrogels of the present technology may also be suitable for in vivo applications (e.g., animal studies). For example, the 3D printed hydrogels of the present technology can be used in in situ and subcutaneous models, with or without cells.

[0178] Example

[0179] The following examples illustrate the beneficial effects achieved by the present technology and 3D printed hydrogels using the present technology and should not be considered limiting.

[0180] Material

[0181] 4-arm PEG maleimide (PEG-Mal, MW 5, 10 and 20 kDa, JenKem), PEG dithiol (MW 1 kDa, Sigma Aldrich), gelatin (from bovine, fish or porcine, Sigma-Aldrich), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC, Sigma-Aldrich), N-hydroxysulfosuccinimide (sulfoNHS, Sigma Aldrich), sodium hydroxide (NaOH), CRGDS, CIKVAV, CYIGSR, GCRDGPQGIWGQDRCG, GCRDPLGLDRCG, and GCIPVSLRSGCG (>90%, Genscript) phosphate buffered saline without calcium chloride (PBS, Gibco), Dulbecco's modified Eagle's medium (DMEM, Gibco), calcium-free DMEM (Gibco), sodium pyruvate (Gibco), L-glutamine (Gibco), trypsin (SigmaAldrich), 0.22 μm syringe filter (polyethersulfone membrane, Merck Millipore, T75 and T150 flasks (Corning), 15 ml centrifuge tubes (Corning), ethanol (Merck Millipore) were used as received.

[0182] Example 1 - Preparation of PEG-Mal polymer bio-ink

[0183] Example 1a - Preparation of polymer bio-ink in PBS

[0184] Three PEG-Mal polymer bioinks were prepared in PBS buffer.

[0185] PEG-Mal polymer bio-ink

[0186] PEG-Mal polymer bio-ink was prepared by mixing PEG-Mal polymer (7.5 wt %) with PBS buffer solution at room temperature. After complete dissolution, the solution was sterile filtered through a 0.22 μm syringe filter.

[0187] PEG-RGD polymer bio-ink

[0188] RGD-containing PEG-Mal (PEG-RGD) polymer bioink was prepared by mixing CRGDS with PEG-Mal (10 wt %) in PBS buffer at room temperature with a total RGD concentration of 5 mM. The reaction was confirmed to be complete by Ellman analysis when no free thiol was recorded. The reaction product, containing PEG-RGD at 10 wt % and 5 mM RGD concentration, was dissolved in PBS. After complete dissolution, NaOH was added to the solution at an equimolar concentration to the RGD concentration to a pH of 7.4. The solution was sterilized by sterile filtration using a 0.22 μm syringe filter.

[0189] PEG-tripeptide polymer bio-ink

[0190] CRGDS, CIKVAV and CYIGSR (at the desired molar concentration) were mixed with PEG-Mal (15 wt%) in PBS buffer at room temperature for 30 minutes to obtain 15 wt% PEG-Mal and 0.67 mM RGD, IKVAV and YIGSR, thereby preparing PEG-Mal-containing RGD, IKVAV and YIGSR (PEG tripeptide) polymer bio-ink. After complete dissolution, the pH of the solution was increased to 7.4 by dropwise addition of 1 M NaOH. The resulting solution was then sterile filtered through a 0.22 μm syringe filter.

[0191] Figure 2 The analysis of 4-arm PEG-Mal modification using CRGDS is shown. UV analysis shows that at the beginning of the reaction, there is a clear peak at 412 nm ( Figure 2 (a)). This indicates the presence of TNB 2- (2-nitro-5-thiobenzoate) ion, which is produced when the disulfide bond of the Ellman's reagent is cleaved and ionized by the thiol group (CRGDS in this case). In contrast, there is no such peak on the 4-arm PEG-Mal solution without CRGDS, and the reaction is allowed to proceed for 20 minutes, indicating that 4-arm PEG-Mal has not reacted with Ellman's reagent and CRGDS has completely reacted after 30 minutes, respectively. By comparing the amide and maleimide proton peaks ( Figure 2 (b)), use 1 H NMR confirmed the quantification of CRGDS conjugation.

[0192] Example 1b - Preparation of polymer bioink in cell culture medium

[0193] Using a suitable cell culture solution for the cells to be printed instead of the PBS solution, a PEG-Mal polymer bio-ink containing RGD in a cell culture medium was prepared according to the procedure of Example 1. The obtained polymer bio-ink was aseptically sterilized by filtration (0.22 μm filter).

[0194] The polymer bio-ink prepared according to Example 1 was stored at -20°C for future use. The polymer bio-ink can be stored at -20°C for at least 6 months without affecting functionality.

[0195] Example 2 - Preparation of PEG Dithiol and GCIPVSLRSGCG Activators

[0196] Example 2a - Preparation of Activator in PBS

[0197] The activator was prepared by mixing dithiothreitol (DTT), PEG dithiol, GCIPVSLRSGCG and GCRDPLGLDRCG, or various combinations thereof, in PBS at an equimolar concentration of the total thiol to the maleimide concentration of the complementary polymer bio-ink. The resulting solution was sterilized by sterile filtration through a 0.22 μm syringe filter.

[0198] Example 2b - Preparation of activators in cell culture medium

[0199] The activator was prepared by mixing dithiothreitol (DTT), PEG dithiol, GCIPVSLRSGCG and GCRDPLGLDRCG in the appropriate cell culture medium for the cells to be printed, with the total thiol concentration being equimolar to the maleimide concentration supplementing the bio-ink. The resulting solution was sterilized by filtration (0.22 μm filter).

[0200] The activator prepared according to Example 2 was stored at -20°C for future use. The activator can be stored at -20°C for at least 6 months without affecting functionality.

[0201] Example 3 - Cell culture

[0202] SK-N-BE (2) (human neuroblastoma), Kras G12D and p53 R172H (pancreatic ductal adenocarcinoma), MCF (human breast cancer) and U87vIII (human glioblastoma) cells were stored in 10% fetal calf serum (FCS) / DMEM, respectively. Under 37°C / 5%CO2 conditions, human non-small cell lung cancer H460 cells were cultured in Roswell Park Memorial Institute (RPMI) 1640 culture medium and 10% FCS (37°C / 5%CO2). Cell lines were routinely screened and free of mycoplasma contamination.

[0203] Example 4 - Trypan Blue Exclusion

[0204] SK-N-BE (2), Kras, and WT mice cultured according to Example 3 were harvested from T75 flasks using trypsin / PBS. G12D and p53 R172H , H460, and U87vIII cells were pelleted by centrifugation. The cells were resuspended in a polymer bioink containing PEG-Mal and PEG-RGD at a concentration of 10 wt %, RGD at a concentration of 5 mM, and a cell concentration of 2 × 10 6 cells / mL. The samples were divided into two groups: a printed sample group and a non-printed control group. The printed sample group was passed through a 3D bioprinter and kept sterile at room temperature for 30 minutes. Dead cells were identified using 0.4% Trypan blue stain (Invitrogen). Cell counts were obtained by calculating the number of live and dead cells in each sample. Cell viability was determined by dividing the total number of live cells by the total number of cells (live + dead).

[0205] Example 5 - Preparation of Cell Polymer Bio-ink

[0206] The cultured cells of interest that have reached a certain degree of confluence are harvested according to the procedure of Example 4. To prepare the cell polymer bio-ink, the harvested cells are resuspended in the sterilized polymer bio-ink prepared according to Example 1(a) or 1(b) at an appropriate cell concentration, and 2×10 6 cells / mL.

[0207] Example 6 - Preparation of cell activators

[0208] The cultured cells of interest that have reached a certain degree of confluence are harvested according to the procedure in Example 4. To prepare a cell activating agent, the harvested cells are resuspended in a sterilized activating agent prepared according to Example 2(a) or 2(b) at an appropriate cell concentration.

[0209] Example 7-3D Cell Viability Assay

[0210] Live / dead staining was used to monitor the viability of hydrogel-encapsulated cells. Calcein AM (1 μL mL -1 ) and homodimer ethidium I (4 μL mL -1 ) to stain live and dead cells, respectively. The cell polymer bio-ink prepared according to Example 5 was used to 3D bioprint hydrogels with encapsulated cells. After the desired incubation period, the bioprinted hydrogels were incubated with live / dead stain at 37°C / 5% CO2 for at least 2 hours before confocal fluorescence microscopy analysis.

[0211] Example 8 - Rheological properties

[0212] The mechanical properties of hydrogels prepared from 4-arm PEG-Mal hydrogel with 5 mM RGD (10 wt %) (prepared according to Example 1(a)) and cross-linked with PEG dithiol and MMP-2 responsive dicysteine ​​peptide GCIPVSLRSGCG cross-linked (mixed at 50:50 thiol molar concentration) (prepared according to Example 2(a)) were studied.

[0213] The rheological properties of the hydrogels were measured using an Anton-Paar Modular Compact Rheometer (MCR) 302 equipped with a concentric cylindrical spindle and cup system. 1 The viscosity measurements were performed at shear rate values ​​of . The rheological properties of the hydrogels were measured using the same machine equipped with a parallel plate geometry (25 mm diameter) system and a solvent collector to minimize liquid evaporation. Rheological measurements were performed on a preheated plate and kept at a constant temperature of 37°C. Amplitude strain sweep experiments (γ: 1100%) were performed to determine the linear viscoelastic region (LVR) at a fixed frequency of 10 Hz. Once the LVR of each sample was determined, a dynamic frequency sweep (ω: 0.1-10 Hz) was performed at a fixed strain in the linear viscoelastic region of the hydrogel. Time sweep measurements were typically performed at a fixed frequency (10 Hz) and strain amplitude (within the LVR).

[0214] like Figure 3 As shown, the frequency ( Figure 3 (a)) and strain ( Figure 3 (b) Scanning studies confirmed that the mechanical properties of the gels were independent of these two parameters.

[0215] The stiffness was then measured at constant frequency and strain values ​​within the viscoelastic region of the hydrogel ( Figure 3 (c)). Measurements were performed within 1 min after hydrogel casting. Figure 3 (c) shows that the storage modulus (G') value is always higher than the loss modulus (G") value during the entire measurement period. The constant storage modulus value at approximately 1.1 kPa indicates that the gelation process is completed within 1 min. Viscosity studies of the polymer bioink and activator show that the viscosity values ​​are less than 10 cP, making both the polymer bioink and activator very suitable for drop-on-demand bioprinting processes ( Figure 3 (d)).

[0216] The mechanical properties of hydrogels prepared from 4-arm PEG Mal blank polymer bio-ink (prepared according to Example 1(a)) and cross-linked with PEG dithiol (prepared according to Example 2(a)) and hydrogels prepared from PEG tripeptide (prepared according to Example 1(a)) and cross-linked with MMP sensitive activator (GCIPVSLRSGCG) (prepared according to Example 2(a)) were also studied. Figure 4 (a)) and PEG-tripeptide hydrogel ( Figure 4 (b) Stiffness was measured at constant frequency and strain values ​​in the viscoelastic region of the hydrogel. The measurements were performed within 1 minute after the hydrogel was cast. Figure 4 (a) and 4(b) show that the storage modulus (G') value is always higher than the loss modulus (G") value throughout the measurement period. This observation confirms the presence of a hydrogel when the bioink and activator are mixed. Quantitatively, the hardness value of the hydrogel formed by the PEG-Mal blank polymer bioink and the PEG-dithiol activator is approximately 0.2 kPa, and the hardness value of the PEG-tripeptide / MMP sensitive hydrogel is approximately 1.6 kPa.

[0217] Example 9 - 3D bioprinting platform

[0218] The components of the 3D bioprinter used in this embodiment include a 3-axis motion console, a droplet dispensing system on demand, and a pressure regulator to control the pressure in the reservoir. The droplet dispensing system and the 3-axis motion console can be placed in a sterile room such as a laminar flow cabinet. The printing platform includes an adapter that allows printing on a variety of substrates, such as microplates and culture dishes. The printing platform can be heated to 37°C to assist cell proliferation.

[0219] A three-axis motion console (MX80S, Parker) enables precise positioning of the droplet dispensing systems in all three dimensions (X, Y, and Z) with a resolution of 10 μm. The ten droplet dispensing systems consist of solenoid valves (VHS series solenoid valves, Lee Corporation) and gemstone orifice dispensing nozzles (MINSTAC nozzles, Lee Corporation) controlled by a microcontroller (Arduino Mega 2560, Arduino). The inner diameter of the gemstone orifice nozzle can be 127 to 254 μm, depending on the fluid viscosity and the desired droplet volume. Each droplet dispensing system is connected to a static pressure reservoir for dispensing polymer bioink and activator solutions through a flexible tube. The desired droplet volume can also be adjusted using the back pressure in the reservoir and the solenoid valve opening time. Typically, the back pressure is set to a pressure between 1 and 300 kPa, the solenoid valve opening time is 0.3 ms or longer, and the droplet volume is 1 to 500 nL. The flexible tubes connecting the polymer bioink and activator containers should be kept as short as possible to minimize the time required to start the system and purge the system at the end of the printing routine.

[0220] Example 10 - Control Software

[0221] The 3D bioprinter was controlled by custom software developed for printing bioanalytical assays. The software included a graphical user interface (GUI) and was written in the Python programming language. Through the GUI, the end user could select different assay printing programs and change assay parameters such as droplet spacing and droplet volume. The user could also manually control the spatial position of the droplet dispensing system and create customized droplet patterns. Additional features of the software included procedures for priming and cleaning the droplet dispensing system.

[0222] Example 11 - 3D bioprinting

[0223] Warm sterile polymer bio-ink and activator to room temperature before printing. Mix cells of interest with polymer bio-ink and / or activator at the desired cell concentration. Then load all solutions into the bioprinter sample tray. Use Rastrum TM Bioprinting was performed using a modular 3D bioprinter (Inventia Life Science (ILS)). The structure was created using Rastrum TM The software (ILS) was used to design the bioprinting samples; two different bioprinting samples were printed: a cylindrical structure with a diameter of approximately 6.35 cm and a thickness of 400 μm and a hemispherical structure with a diameter of 100 μm on top of an inert gel layer with a diameter of 6.35 cm and a thickness of 100 μm. Both the polymer bioink and the activator solution were printed at a printing pressure of 20-100 kPa. Prior to the bioprinting process, the bioprinter was first subjected to an automatic sterilization and priming step.

[0224] The generation of 3D objects was achieved by depositing droplets of polymer bioink, followed immediately by depositing droplets of activator on top of them at locations determined by the software. All printing was performed in 96-well plates (Corning). Upon completion, the relevant cell culture medium for the cells was added (150 μL) and the plates were transferred to an incubator.

[0225] Figure 1 is a representative schematic diagram of the 3D bioprinting process. The polymer bio-ink used comprises 4-arm PEG maleimide (PEG-Mal), CRGDS and the desired cancer cells (prepared according to Examples 1(a) and 5). The activator comprises a mixture of PEG dithiol and dithiol MMP responsive peptide GCIPVSLRSGCG (prepared according to Example 2(a)). According to Example 9, the two solutions are loaded into the ILS 3D bioprinter system, which deposits the combination of polymer bio-ink and activator in a spatially controlled manner. The two solutions gelate immediately after mixing, thereby producing three-dimensional encapsulated cells inside the hydrogel in a 96-well plate.

[0226] Example 12 - Pancreatic ductal adenocarcinoma cells (Kras G12D and p53 R172H 3D bioprinting

[0227] The ILS 3D bioprinter was used to bioprint multiple three-dimensional encapsulated cancer cell samples within thiolmaleimide cross-linked PEG hydrogels. Specifically, the bioprinter was used to simultaneously deliver cancer cells, polymer bio-ink, and activators to rapidly form in situ cell encapsulation within the bioprinted hydrogels.

[0228] Cell culture

[0229] Pancreatic ductal adenocarcinoma cells Kras at 80% confluence in T150 flask G12D and p53 R172H Wash with 3 mL PBS. After aspirating excess PBS, add 3 mL trypsin and incubate the flask at 37°C to detach the cells from the flask surface for 5 minutes. Subsequently, add 7 mL of tissue culture medium prepared by mixing DMEM with FCS at 10 v / v%, and transfer the detached cells to a 15 mL tube. Centrifuge the cell dispersion at 400 g for 3 minutes. Discard the supernatant and resuspend the cell pellet in 5 mL culture medium. Then count the cells by mixing equal volumes of the cell suspension and trypan blue stain to determine the cell concentration.

[0230] Base

[0231] Use the 96-well plate as provided by Corning Incorporated. Open the sterile packaging in a sterile environment to maintain the sterility of the contents.

[0232] Polymer Bioink

[0233] To prepare the polymer bio-ink, PEG-Mal (0.150 g) was dissolved in 1.5 mL PBS to produce a 10 wt% polymer bio-ink. If PEG-RGD was to be added, CRGDS (1.34 mg) was added to the solution and stirred for 30 minutes to produce a 10 wt% PEG-Mal / PEG-RGD polymer bio-ink containing 5 mM RGD. 2.5 μL 1 M NaOH was added to the solution to raise the pH of the solution to 7.4. The solution was then filtered through a 0.22 μm syringe filter under a sterile environment.

[0234] Will be 2×10 6 Kras cells / mL concentration dispersed in 1 mL DMEM G12D and p53 R172HCentrifuge to obtain a cell pellet of 500,000 cells. The obtained pellet is then redispersed in polymer bio-ink (1 mL) to obtain a cell polymer bio-ink solution containing dispersed Kras G12D and p53 R172H Cells, concentration 2×10 6 cells / mL.

[0235] Activator

[0236] To prepare non-MMP and MMP-responsive hydrogels, two different activators were prepared. These two activators were prepared from PEG dithiol alone (0.01975 g) or a combination of PEG dithiol (0.0096 g) and GCIPVSLRSGCG (0.0111 g), each activator was dissolved in 1 mL PBS to produce an activator in which the thiol concentration was equimolar to the maleimide concentration in the bio-ink. Each solution was then filtered through a 0.22 μm syringe filter under sterile conditions.

[0237] Cell printing conditions

[0238] The cell-polymer bio-ink and activator are loaded into the relevant ink cartridges and connected to the bio-printer. Both the cell-polymer bio-ink and activator are connected to a 0.007-inch nozzle with an operating pressure of 10 Psi.

[0239] The printer was initially cleaned by wiping with ethanol (70 v / v% in water) and air dried. Fluid lines, valves, and nozzles were also sterilized by sequentially washing with ethanol, water, and tissue culture medium. Cell-polymer bio-ink and activator were then loaded into their respective vials. The print head was then primed before starting the printing process.

[0240] The 3D structure of the assay was designed using ILS custom software. The 3D assay consisted of 3 layers of circular gel with a total diameter of 6.35 mm. The 3D assay was bioprinted by repeatedly depositing a drop of polymer bioink and activator at a determined location using the software.

[0241] Cell concentration

[0242] The concentration used in this experiment was 2×10 6 cells / mL of cell-polymer bioink.

[0243] Cell viability

[0244] A cell viability of greater than or equal to 95% was obtained.

[0245] Example 13 - 3D bioprinting of human breast cancer cells (MCF7)

[0246] Cell culture

[0247] 80% fused MCF7 cells were washed with 3mL PBS in a T75 flask. After inhaling excess PBS, 1mL trypsin was added and the flask was cultivated at 37°C to separate the cells from the flask surface for 3 minutes. Subsequently, 7mL of tissue culture medium prepared by mixing DMEM with FCS at 10v / v% was added, and the separated cells were transferred to a 15mL tube. The cell dispersion was centrifuged at 400g for 3 minutes. Supernatant was discarded and the cell pellet was resuspended in 5mL culture medium. Cell count was then performed to determine cell concentration by mixing an equal volume cell suspension with a trypan blue colorant.

[0248] Base

[0249] Use the 96-well plate as provided by Corning Incorporated. Open the sterile packaging in a sterile environment to maintain the sterility of the contents.

[0250] Polymer Bioink

[0251] To prepare the blank polymer bio-ink, PEG-Mal (0.1125 g) was dissolved in 1.5 mL of PBS to obtain a 7.5 wt% polymer bio-ink. CRGDS (0.54 mg), CIKVAV (0.64 mg), CYIGSR (0.70 mg) and PEG-Mal (0.225 g) were mixed in 1.5 mL of PBS for 30 min to obtain a 15 wt% PEG tripeptide with 0.67 mM each of RGD, IKVAV and YIGSR. The pH of the solution was raised to 7.4 by adding 1 M NaOH dropwise. Both solutions were sterile filtered through a 0.22 μm syringe filter.

[0252] Activator

[0253] To prepare non-MMP and MMP-responsive hydrogels, two different activators were prepared. These two activators were prepared from PEG-dithiol (0.015 g) or GCRDPLGRDRCG (0.019 g), each dissolved in 1 mL PBS to obtain activators, respectively, with the thiol concentration in the activator being equimolar to the maleimide concentration in the blank bio-ink and PEG-tripeptide. Subsequently, the MMP-responsive activator solution was adjusted to pH 7.4 by dropwise addition of 1 M NaOH. Each solution was then sterile filtered through a 0.22 μm syringe filter.

[0254] The harvested MCF7 dispersed in 1 mL of DMEM was centrifuged to obtain a cell pellet of 10,000,000 cells. The obtained pellet was then redispersed in an activator (1 mL) to obtain a cell MMP activator solution containing dispersed MCF7 at a concentration of 1×10 7 cells / mL.

[0255] Cell printing conditions

[0256] The polymer bio-ink, PEG dithiol activator, and MMP-responsive cell activator were loaded into the relevant ink cartridges and connected to the bioprinter. The polymer bio-ink, PEG dithiol activator, and MMP-responsive cell activator were connected to a 0.007-inch nozzle, respectively, with an operating pressure between 25 and 30 kPa.

[0257] The printer was initially cleaned by wiping with ethanol (70 v / v% in water) and air dried. Fluid lines, valves, and nozzles were also sterilized by sequential ethanol and sterile water washes. The polymer bio-ink, PEG dithiol activator, and MMP-responsive cell activator were then loaded into their respective vials. The printhead was then primed before starting the printing process.

[0258] The 3D structure for the analysis was designed using ILS custom software. The 3D analysis consisted of a bottom gel layer with a diameter of 6.35 cm and a thickness of 100 μm and a cell-filled dome-shaped gel with a diameter of 1 mm and a thickness of 200 μm.

[0259] Cell concentration

[0260] The concentration used in this experiment was 1×10 7 cells / mL of cell activator.

[0261] Cell viability

[0262] A cell viability of greater than or equal to 95% was achieved.

[0263] Example 14 - Comparison of cell arrangements

[0264] The effects of the hydrogel microenvironment on the alignment of pancreatic cancer cells were tested using polymer bioinks and activators of this technology. Pancreatic cancer cells were chosen because their biological properties are highly dependent on the cell culture environment. Two different cell arrangements were tested by bioprinting hydrogel samples with a diameter of 6 mm and a height of 0.4 mm on a 96-well plate. In the first, cells were 3D bioprinted on top of the hydrogel, and in the second, cells were printed inside the hydrogel (i.e., encapsulated in the hydrogel). In both cell arrangement tests, living cells were observed. In addition, cell-gel interactions were visible, represented by the ability of the cells to form protrusions into the hydrogel. Overall, bioprinting for biocompatible and bio-relevant 3D analysis was successfully performed using PEG-based polymer bioinks.

[0265] Pancreatic cancer cells seeded on top of the hydrogel

[0266] Pancreatic ductal adenocarcinoma cells (Kras G12D and p53 R172H ) and 4-arm PEG-Mal (10 kDa) were used to prepare cell polymer bio-ink, of which 5 mM RGD polymer bio-ink was used for 3D bioprinting. Pancreatic cancer cells were dispersed in the cell polymer bio-ink at a concentration suitable for seeding about 5,000 cells / well.

[0267] The acellular hydrogels were initially formed by 3D bioprinting of 4-arm PEG-Mal (10 kDa) with 5 mM RGD polymer bioink with PEG dithiol and MMP-2 (GCIPVSLRSGCG) activator (thiol concentration ratio of 50:50) in 96-well plates. Cellular polymer bioink was then printed on top of the hydrogels with PEG dithiol and MMP-2 activator (thiol concentration ratio of 50:50) to seed approximately 5,000 cells / well.

[0268] Microscopic observation of pancreatic cancer cells seeded on top of hydrogels. After 3 days of incubation, the morphological differences when the same cells were seeded on top of tissue culture materials were observed. When seeded on top of hydrogels, both cell-gel and cell-cell interactions were promoted, resulting in the formation of an extended cell network with extensive cell processes in all three dimensions. After 3 days of incubation, the viability of the cultured cells was confirmed by a live / dead staining assay. It was confirmed that the cell viability was >98%, and small single dead cells were clearly visible among the larger population of live cells.

[0269] Pancreatic cancer cells were also seeded on various substrates for comparison. Microscopic images showed that pancreatic cancer cells seeded on tissue culture wells were very individualistic. In contrast, when seeded on top of the hydrogel, pancreatic cancer cells formed an expanded network between multiple cells. When seeded on top of the hydrogel, the cells were able to invade the hydrogel and form a 3D cell network. Scanning the gel on the z-axis under the microscope showed that there was a 3D cell network within the hydrogel.

[0270] Pancreatic cancer cells encapsulated in a bioinert hydrogel

[0271] Pancreatic ductal adenocarcinoma cells (Kras G12D and p53 R172H ) with 2×10 6 The concentration of cells / mL was dispersed in polymer bioink without PEG-RGD to produce cell-polymer bioink, which was printed with activator without MMP-2 responsive peptide. In situ encapsulation was achieved by direct 3D bioprinting of cell-bioink with PEG dithiol activator on 96-well plates.

[0272] Confocal images show pancreatic cancer cells encapsulated inside the hydrogel. The morphology of the cells during the incubation period was confirmed. Due to the lack of RGD and MMP-2 crosslinkers, the morphology of the cells is round inside the gel. This morphology indicates that the cells cannot interact with the hydrogel to form focal adhesions and cannot move inside the gel. Live / dead assay was performed on the encapsulated cells after 3 days of incubation. Fluorescence images show live cells (>95% viability) after 3 days of incubation.

[0273] Pancreatic cancer cells encapsulated in bioactive hydrogels

[0274] Pancreatic ductal adenocarcinoma cells (Kras G12D and p53 R172H ) with 2x10 6 Cells / mL were dispersed in cell-polymer bio-ink and printed with MMP-2 responsive peptide activator (thiol concentration ratio of 50:50). In situ encapsulation was achieved by direct 3D bioprinting of cell-polymer bio-ink with PEG dithiol and MMP-2 activator on 96-well plates. MMP-2 activator was used to allow cell invasion.

[0275] Confocal images show pancreatic cancer cells encapsulated in hydrogels. The morphology of the cells during the incubation period was confirmed. Inside the gel, cell-cell interactions were indicated by the formation of cell clusters, while cell-gel interactions and cell invasion were confirmed by the presence of cell membrane protrusions. Live / dead assays were performed on the encapsulated cells after a 3-day and 6-day incubation period. After 3 days of incubation, bright field and fluorescence images showed live cells (>98% viability) after 3 days of incubation and confirmed the presence of cell-cell and cell-gel interactions. Cell invasion was more obvious at 6 days of incubation, indicating strong cell-gel interactions. At the same time, more than 98% cell viability was maintained after 6 days of incubation in the gel.

[0276] MCF7 breast cancer cells seeded in hydrogel

[0277] After 3 days of incubation, cell viability was confirmed by observing cell morphology under bright field microscopy. After the incubation period, agglomeration of single MCF7 cells was visible, forming multiple spheres in the pre-defined gel area, which demonstrated the ability of single MCF7 cells to move relative to each other within the hydrogel.

[0278] Example 15 - Modification of cold fish skin gelatin with maleimide groups

[0279] Fish skin gelatin (1 g) was dissolved in 20 mL of 2-(N-morpholino)ethanesulfonic acid (MES) buffer at 40°C. In a separate container, 6-maleimidocaproic acid (MHA; 0.211 g), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC, EDC:MHA molar ratio 1::20) and N-hydroxysuccinimide (NHS, 1:2NHS:EDC molar ratio 1:2) were dissolved in 1 mL of MES buffer and stirred for 20 minutes to activate the carboxylic acid (COOH) groups. The activated COOH group solution was then transferred to the gelatin solution and reacted for 24 hours. The resulting solution was purified by dialysis with 10 mM hydrochloric acid (HCl) and 1 wt% sodium chloride (NaCl) for 2 days, and then dialyzed against 10 mM HCl for 1 day. The purified gelatin solution was then freeze-dried to obtain maleimide-modified fish gelatin.

[0280] Example 16 - Modification of Porcine Skin Gelatin with Maleimide Groups

[0281] Porcine skin gelatin (gel strength 300, type A, 1 g) was dissolved in 20 mL of MES buffer at 40°C. In a separate container, MHA (0.139 g), EDC (EDC:MHA molar ratio 1:20) and N-hydroxysuccinimide (NHS, NHS:EDC molar ratio 1:2) were dissolved in 1 mL of MES buffer and kept stirring for 20 minutes to activate the COOH groups. The activated COOH group solution was then transferred to the gelatin solution and reacted for 24 hours. The resulting solution was purified by dialysis with 10 mM HCl and 1 wt% NaCl for 2 days, and then dialyzed with 10 mM HCl for 1 day. The purified gelatin solution was then freeze-dried to obtain maleimide-modified porcine skin gelatin.

[0282] Example 17 - Gelation of maleimide-modified gelatin

[0283] The maleimide-modified gelatins from pig and cold fish skin synthesized in Examples 15 and 16 were each dissolved in PBS at 20 wt% to produce polymer bio-inks. The pH of each solution was neutralized to pH 7.4 with 1 M NaOH. To prepare the activator, PEG-dithiol with an equal molar concentration of SH to that of maleimide was dissolved in PBS. Equal volumes of each polymer bio-ink and activator were mixed to achieve gelation.

[0284] Example 18 - 3D bioprinting of PEG hydrogels containing collagen

[0285] Base

[0286] The cell culture dishes provided by Thermofisher are etched with a target grid that mimics the dimensions of a 96-well plate.

[0287] Polymer Bioink

[0288] To prepare the polymer bio-ink, PEG-Mal (0.15 g) was dissolved in 1.5 mL PBS to obtain a 10 wt% polymer bio-ink. The solution was sterile filtered through a 0.22 μm syringe filter.

[0289] Activator

[0290] GCRDPLGLDRCG (0.01 g) was mixed in 0.5 mL PBS to prepare an activator containing collagen. Subsequently, 0.5 mL type I bovine collagen (3.1 mg) was mixed into the activator solution to produce an MMP activator containing collagen. Subsequently, the pH of the solution was adjusted to pH 7.4 by dropwise addition of 1 M NaOH. The solution was then sterile filtered through a 0.22 μm syringe filter.

[0291] Printing conditions

[0292] The polymer bio-ink and collagen-containing MMP activator were loaded into the relevant ink cartridges and connected to the bioprinter. Both the polymer bio-ink and the activator were connected to a 0.007-inch nozzle with an operating pressure between 25 and 30 kPa.

[0293] The 3D structure analyzed was designed using ILS custom software. The 3D rectangular prism structure consisted of a bottom gel layer with a length and width of approximately 4.5 cm and a thickness of 150 μm.

[0294] Structural Verification

[0295] The resulting hydrogel structures were imaged using a USB digital microscope.

[0296] Example 19 - Fibroblast Culture in Collagen Containing PEG Hydrogels

[0297] Polymer bioink with collagen was prepared by mixing type I bovine collagen with 10 wt% PEG-Mal in PBS at a 1:1 v / v ratio. The pH of the solution was raised to 7.4 by dropwise addition of 1 M NaOH solution. PEG dithiol activator containing thiol at equimolar concentration to maleimide was prepared in PBS. Harvested human lung fibroblasts (MRC-5) were pelleted and resuspended in polymer bioink containing collagen. PEG hydrogels were prepared by first transferring the polymer bioink to a well plate and then transferring an equal volume of cell activator to the same well. 100 μL DMEM + 10 v / v% FBS was then added to each well, the samples were cultured for 6 days, and bright field images were taken at day 0, day 3, and day 6 to monitor cell activity.

[0298] The biocompatibility of the gels for fibroblast culture was evaluated by observing the change in fibroblast morphology from round to spindle morphology.

[0299] Those skilled in the art will recognize that the present invention is susceptible to changes and modifications other than those specifically described. It should be understood that the present invention includes all such changes and modifications without departing from the spirit or scope of the present invention as broadly described. Therefore, the present embodiments are considered to be illustrative and not restrictive in all respects.

[0300] The present invention also includes all steps, features, compositions and compounds mentioned or indicated in this specification, individually or collectively, and any and all combinations of any two or more of the steps, features, compositions and compounds.

[0301] References

[0302] 1. Caliari, SR; Burdick, JA. A practical guide to hydrogels for cell culture. Nature Methods 13, 405 (2016).

[0303] 2. Murphy, SV; Atala, A. 3D bioprinting of tissues and organs. Nature Biotechnology 32, 773 (2014).

[0304] 3. Donderwinkel, I.; van Heerst, J.C.M.; Cameron, N.R. Bioinks for 3D bioprinting: recent progress and future perspectives, Polymer Chemistry 8, 4451-4471 (2017).

[0305] 4. Jungst, T.; Smolan, W.; Schacht, K.; Scheibel, T.; Groll, J., Strategies and molecular design criteria for 3D printable hydrogels, Chemical Reviews 116, 1496-1539 (2016).

[0306] 5. Lowe, SB; Tan, VTG; Soeriyadi, AH; Davis, TP; Gooding, JJ. Synthesis and high-throughput processing of polymer hydrogels for 3D cell culture. Bioconjugate Chemistry, 25, 1581-1601 (2014).

[0307] 6. Gao, G.; Hubbell, K.; Schilling, A. F.; Dai, G.; Cui, X., Bioprinting cartilage tissue from mesenchymal stem cells and PEG hydrogels, in 3D Cell Culture: Methods and Protocols, Koledova, Z., ed. New York Times Springer: 2017, New York, NY; pp 391-398.

[0308] 7. Gao G; Yonezawa, T.; Hubbell, K.; Dai, G; Cui, X., Inkjet bioprinting of acrylated peptides and PEG hydrogels with human mesenchymal stem cells promotes robust bone and cartilage formation and minimizes printhead clogging, Journal of Biotechnology 10, 1568-1577 (2015).

Claims

1. A drop-on-demand 3D printing hydrogel, formed by a maleimide-containing polymer cross-linked with a dithiol cross-linker having at least two thiol functional groups, the maleimide-containing polymer being selected from PEG maleimide, gelatin maleimide, or a combination thereof, wherein: The hydrogel is printed from a maleimide-containing polymer and a cross-linking agent in 1 second or less; NaOH is used to adjust the pH of the maleimide-containing polymer and / or the cross-linking agent.

2. The 3D printed hydrogel according to claim 1, wherein: The maleimide-containing polymer includes PEG maleimide.

3. The 3D printed hydrogel according to claim 1, wherein: The maleimide-containing polymer includes gelatin maleimide.

4. The 3D printed hydrogel according to claim 1, wherein: The dithiol-containing cross-linking agent is selected from the group consisting of synthetic polymers, biopolymers, small molecules, bioactive molecules, and any combination thereof.

5. The 3D printed hydrogel according to claim 4, wherein: The dithiol crosslinking agent is selected from PEG dithiol, A metalloproteinase responsive peptide, or a combination thereof.

6. The 3D printed hydrogel according to claim 5, wherein: The dithiol-containing cross-linking agent is PEG-dithiol.

7. The 3D printed hydrogel according to claim 5, wherein: The dithiol-containing cross-linking agent is a matrix metalloproteinase responsive peptide.

8. The 3D printed hydrogel according to claim 7, wherein: The matrix metalloproteinase-responsive peptide is a MMP-responsive dicysteine ​​peptide.

9. The 3D printed hydrogel according to claim 8, wherein: The MMP-responsive peptide is selected from GCIPVSLRSGCG, GCRDGPQGIWGQDRCG, GCRDPLGLDRCG, GCRDEAPLKQDRCG, and any combination thereof.

10. The 3D printed hydrogel according to claim 9, wherein: The MMP-responsive peptide is GCIPVSLRSGCG, GCRDPLGLDRCG, or a combination thereof.

11. The 3D printed hydrogel according to claim 2, wherein: The maleimide-containing polymer is PEG-maleimide substituted with at least one bioactive molecule selected from RGD, YIGSR and IKVAV.

12. The 3D printed hydrogel according to claim 3, wherein: The maleimide-containing polymer is gelatin maleimide, and the dithiol-containing cross-linking agent is PEG-dithiol.

13. The 3D printed hydrogel according to claim 1, wherein: The molar ratio of the maleimide-containing polymer to the dithiol-containing crosslinking agent is in the range of 10:1 to 1:

10.

14. The 3D printed hydrogel according to any one of claims 1 to 13, comprising cells.

15. The 3D printed hydrogel according to claim 14, wherein: The cells are suspended within a portion of the hydrogel or the cells are uniformly suspended throughout the hydrogel.

16. The 3D printed hydrogel according to claim 15, wherein: The concentration range of printed cells was 1 × 10 5 Up to 5× 10 8 cells / mL.

17. The 3D printed hydrogel according to claim 14, wherein: The cells are selected from the group consisting of hepatocytes, gastrointestinal cells, pancreatic cells, kidney cells, lung cells, tracheal cells, vascular cells, skeletal muscle cells, cardiomyocytes, skin cells, smooth muscle cells, connective tissue cells, corneal cells, urogenital cells, breast cells, germ cells, endothelial cells, epithelial cells, fibroblasts, neural cells, Schwann cells, adipocytes, bone cells, bone marrow cells, chondrocytes, pericytes, mesothelial cells, endocrine tissue-derived cells, stromal cells, stem cells, progenitor cells, lymphocytes, blood cells, endoderm-derived cells, ectoderm-derived cells or mesoderm-derived cells, and any combination thereof.

18. The 3D printed hydrogel according to any one of claims 1 to 13, further comprising a bioactive molecule.

19. The 3D printed hydrogel according to claim 18, wherein: The biomolecule is a free bioactive molecule, or is bound to a maleimide-containing polymer or a dithiol-containing cross-linking agent, or is bound to both a maleimide-containing polymer and a dithiol-containing cross-linking agent.

20. The 3D printed hydrogel according to claim 19, wherein: The bioactive molecule is selected from peptides, MMP-responsive peptides, proteins, polysaccharides, drugs, therapeutic agents, antibodies, small molecule inhibitors, kinase inhibitors, phosphatase inhibitors, antigens, pathogens, platelets, growth factors, cytokines, amino acids, nutrients, conditioned media, antibiotics, antiviral drugs, RNA, and any combination thereof.

21. The 3D printed hydrogel according to claim 20, wherein: The bioactive molecule is collagen.

22. The 3D printed hydrogel according to any one of claims 1 to 13, further comprising a cell culture medium.

23. The 3D printed hydrogel according to claim 1, wherein: Prior to printing, the pH of the maleimide-containing polymer and / or cross-linking agent was adjusted to 6.5-7.5 using NaOH.

24. The 3D printed hydrogel according to claim 1, wherein: Prior to printing, the pH of the maleimide-containing polymer and / or cross-linking agent was adjusted to 7.4 using NaOH.

25. The 3D printed hydrogel according to claim 1, wherein: The 3D printed hydrogels have a generally uniform 3D structure.

26. The 3D printed hydrogel according to claim 1, wherein: The 3D printed hydrogels were formed without the assistance of any co-reactants.

27. A method for preparing a drop-on-demand 3D printed hydrogel, the method comprising: Providing a polymer bio-ink, the polymer bio-ink comprising a maleimide-containing polymer, the maleimide-containing polymer being selected from PEG maleimide, gelatin maleimide, or a combination thereof; Providing an activator, the activator comprising a dithiol crosslinker having at least two thiol functional groups; printing the polymer bio-ink and the activator using a drop-on-demand printing method, wherein a drop of the polymer bio-ink is applied to a substrate, followed by a drop of the activator to form a hydrogel, or a drop of the activator is applied to a substrate, followed by a drop of the polymer bio-ink to form a hydrogel drop; Repeatedly deposit a drop of polymer bio-ink and activator on the hydrogel droplet to form a 3D printed hydrogel; Among them, the hydrogel is printed from polymer bio-ink and activator in 1 second or less; The pH of the maleimide-containing polymer and / or cross-linking agent is adjusted with NaOH.

28. The method of claim 27, further comprising providing cells during the printing process to form a 3D printed hydrogel containing cells.

29. The method according to claim 28, wherein: Prior to 3D printing, the cells are present in the polymer bio-ink, in the activating agent, in both the polymer bio-ink and the activating agent, or in a separate medium.

30. The method of claim 27, wherein: The polymer bio-ink, the activator, or both were adjusted to pH 7.4 prior to printing.

31. The method according to claim 30, wherein: The pH was adjusted using NaOH.

32. A cell analysis method comprising the cell-containing 3D printed hydrogel according to claim 14.

33. Use of the cell-containing 3D printed hydrogel according to claim 14 for cell analysis.

Citation Information

Patent Citations

  • Process for printing 3D tissue culture models

    CN107922921A

  • Microgels for Encapsulation of Cells and Other Biologic Agents

    US20150071997A1

  • Poly(ethylene glycol) cross-linking of soft materials to tailor viscoelastic properties for bioprinting

    US20150084232A1